Illumina (NASDAQ:ILMN) Director Keith Meister Sells 214,596 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 214,596 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $163.51, for a total value of $35,088,591.96. Following the sale, the director directly owned 3,065,452 shares in the company, valued at $501,232,056.52. The trade was a 6.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Illumina Trading Up 0.9%

Shares of NASDAQ ILMN opened at $164.40 on Tuesday. The business’s 50 day moving average is $134.48 and its two-hundred day moving average is $132.39. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. Illumina, Inc. has a 1-year low of $78.79 and a 1-year high of $165.97. The stock has a market capitalization of $24.87 billion, a P/E ratio of 29.89, a PEG ratio of 2.70 and a beta of 1.50.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, April 30th. The life sciences company reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The company had revenue of $1.09 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the firm posted $0.97 earnings per share. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, research analysts expect that Illumina, Inc. will post 5.2 EPS for the current year.

Key Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Guggenheim raised its price target on Illumina to $180 from $170 and kept a Buy rating, signaling continued confidence in the company’s upside potential and valuation. Benzinga article
• Positive Sentiment: Integrated DNA Technologies said its oncology research workflows are now optimized on Illumina software, which could support broader adoption of Illumina’s ecosystem and strengthen its positioning in cancer research tools. Business Wire article
• Neutral Sentiment: Chief accounting officer Scott D. Ericksen sold a small number of shares under a pre-arranged Rule 10b5-1 plan; while routine, it adds to recent insider selling activity. SEC filing
• Negative Sentiment: Director Keith A. Meister sold a very large block of Illumina shares in multiple transactions around May 28-June 1, reducing his stake materially. Large insider sales can weigh on sentiment even when they do not necessarily reflect operational weakness. SEC filing

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on ILMN shares. Piper Sandler dropped their target price on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research report on Monday, February 9th. Citigroup boosted their target price on Illumina from $80.00 to $95.00 and gave the company a “sell” rating in a research report on Monday, May 4th. UBS Group restated a “neutral” rating and set a $135.00 target price on shares of Illumina in a research report on Friday, February 6th. Barclays boosted their target price on Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a research report on Friday, May 1st. Finally, Weiss Ratings lowered Illumina from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, April 29th. Seven research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, Illumina currently has an average rating of “Hold” and a consensus price target of $138.38.

Institutional Trading of Illumina

Large investors have recently modified their holdings of the company. Elyxium Wealth LLC purchased a new stake in shares of Illumina in the fourth quarter valued at approximately $25,000. Board of the Pension Protection Fund purchased a new stake in shares of Illumina in the fourth quarter valued at approximately $26,000. Creative Capital Management Investments LLC boosted its holdings in shares of Illumina by 160.0% in the fourth quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 120 shares during the period. TD Waterhouse Canada Inc. purchased a new stake in shares of Illumina in the fourth quarter valued at approximately $26,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in shares of Illumina in the fourth quarter valued at approximately $26,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.